R. A. Spence, W. M. Kati, K. S. Anderson, and K. A. Johnson, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors, Science, vol.267, pp.988-993, 1995.

N. Sluis-cremer and G. Tachedjian, Mechanisms of inhibition of HIV replication by nonnucleoside reverse transcriptase inhibitors, Virus Res, vol.134, pp.147-156, 2008.

S. G. Sarafianos, B. Marchand, K. Das, D. M. Himmel, M. A. Parniak et al., Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition, J. Mol. Biol, vol.385, pp.693-713, 2009.

J. R. Brechtl, W. Breitbart, M. Galietta, S. Krivo, and B. Rosenfeld, The use of Highly Active Anti Retroviral Therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care and quality of life outcomes, J. Pain Symptom Manag, vol.21, pp.41-51, 2001.

I. Usach, V. Melis, and J. E. Peris, Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability, vol.16, pp.1-14, 2013.

S. Chander, P. Ashok, Y. T. Zheng, P. Wang, K. S. Raja et al., Design, synthesis and in-vitro evaluation of novel tetrahydroquinolinecarbamates as HIV-1 RT inhibitor and their antifungal activity, Bioorg. Chem, vol.64, pp.66-73, 2016.

Z. Li, B. Terry, W. Olds, T. Protack, C. Deminie et al., In vitro crossresistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations, Antimicrob Agents Chemother, vol.57, pp.5500-5508, 2013.

A. E. Basson, S. Y. Rhee, C. M. Parry, Z. El-khatib, S. Charalambous et al., Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer non-nucleoside reverse transcriptase inhibitors, Antimicrob Agents Chemother, vol.59, pp.960-971, 2015.

K. Singh, B. Marchand, K. A. Kirby, E. Michailidis, and S. G. Sarafianos, Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase, Viruses, vol.2, pp.606-638, 2010.

N. Sluis-cremer, M. A. Wainberg, and R. F. Schinazi, Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection, Future Microbiol, vol.10, pp.1773-1782, 2015.

K. Das, J. D. Bauman, A. D. Clark, Y. V. Frenkel, P. J. Lewi et al., High-resolution structures of HIV-1 reverse transcriptase/ TMC278 complexes: strategic flexibility explains potency against resistance mutations, Proc. Natl. Acad. Sci. USA, vol.105, pp.1466-1471, 2008.

D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat. Rev. Drug Discov, vol.3, pp.935-949, 2004.

E. Lionta, G. Spyrou, D. K. Vassilatis, and Z. Cournia, Structure-based virtual screening for drug discovery: principles, applications and recent advances, Curr. Top Med. Chem, vol.14, pp.1923-1938, 2014.

B. O. Villoutreix, R. Eudes, and M. A. Miteva, Structure-based virtual ligand screening: recent success stories, Comb. Chem. High Throughput Screen, vol.12, pp.1000-1016, 2009.

S. Chander, R. K. Pandey, A. Penta, B. S. Choudhary, M. Sharma et al., Molecular docking and molecular dynamics simulation based approach to explore the dual inhibitor against HIV-1 reverse transcriptase and Integrase, Comb Chem High Throughput Screen, vol.20, 2017.

C. Liao and M. C. Nicklaus, Computer tools in the discovery of HIV-I integrase inhibitors, Future Med. Chem, vol.2, pp.1123-1140, 2010.

G. Hu, X. Li, X. Zhang, Y. Li, L. Ma et al., Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays, J. Med. Chem, vol.55, pp.10108-10117, 2012.

S. Chander, A. Penta, and S. Murugesan, Structure-based virtual screening and docking studies for the identification of novel inhibitors against wild and drug resistance strains of HIV-1 RT, Med. Chem. Res, vol.24, pp.1869-1883, 2015.

S. Chander, C. R. Tang, H. M. Al-maqtari, J. Jamalis, A. Penta et al., Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives, Bioorg. Chem, vol.72, pp.74-79, 2017.

D. Li, P. Zhan, E. De-clercq, and X. Liu, Transcriptase inhibitors: lessons from the development of seven representative paradigms, J. Med. Chem, vol.55, pp.3595-3613, 2012.

S. Chander, P. Wang, P. Ashok, L. M. Yang, Y. T. Zheng et al., Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl) amino)-1-(piperazin-1-yl)ethanone derivatives, Bioorg. Med. Chem. Lett, vol.27, pp.61-65, 2017.

P. Zhan, X. Chen, D. Li, Z. Fang, E. De-clercq et al., HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design, Med. Res. Rev, vol.33, issue.1, pp.1-72, 2013.

S. Chander, P. Ashok, A. Singh, and S. Murugesan, De-novo design, synthesis and evaluation of novel 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as HIV-1 reverse transcriptase inhibitors, Chem. Cent. J, vol.9, 2015.

T. M. Williams, T. M. Ciccarone, S. C. Mactough, C. S. Rooney, S. K. Balani et al., 5-chloro-3-(phenylsulfonyl)indole-2 carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase, J. Med. Chem, vol.36, pp.1291-1294, 1993.

G. L. Regina, A. Coluccia, A. Brancale, F. Piscitelli, V. Gatti et al., Indolyl arylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide, J. Med. Chem, vol.54, pp.1587-1598, 2011.

C. Dousson, F. R. Alexandre, A. Amador, S. Bonaric, S. Bot et al., Discovery of the aryl-phospho-indole IDX899, a highly potent anti-HIV Non-nucleoside reverse transcriptase inhibitor, J. Med. Chem, vol.59, pp.1891-1898, 2016.

R. Storer, F. Alexandre, and C. Dousson, inventors; Idenix Pharmaceuticals, Inc. assignee. Enatiomerically pure phosphoindoles as HIV inhibitors. United States patent, 2008.

M. Hassam, A. E. Basson, D. C. Liotta, L. Morris, W. A. Van-otterlo et al., Novel cyclopropyl-indole derivatives as HIV non-nucleoside reverse transcriptase inhibitors, ACS Med. Chem. Lett, vol.3, pp.470-475, 2012.

O. S. Pedersen and E. B. Pedersen, Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom, Antivir Chem. Chemother, vol.10, pp.285-314, 1999.

M. L. Barreca, A. Rao, L. De-luca, N. Iraci, A. M. Monforte et al., Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains, Bioorg. Med. Chem. Lett, vol.17, pp.1956-1960, 2007.

A. K. Gupta, S. Kalpana, and J. K. Malik, Synthesis and in vitro antioxidant activity of new 3-substituted-2-oxindole derivatives, Indian J. Pharm. Sci, vol.74, pp.481-486, 2012.

M. Bai, Y. You, Y. Z. Chen, G. Y. Xiang, X. Y. Xu et al., An unprecedented protocol for the synthesis of 3-hydroxy-3-phenacyloxindole derivatives with indolin-2-ones and ?-substituted ketones, Org. Biomol. Chem, vol.14, pp.1395-1401, 2016.

H. M. Meshram, P. B. Thakur, M. B. Bejjam, and V. M. Bangade, mediated Henry reaction of isatins: an efficient synthesis of 3-hydroxy-2-oxindole, Green Chem. Lett. Rev, vol.6, pp.19-43, 2013.

N. Kumar, J. Kaur, A. Kumar, N. Islam, and S. S. Chimni, Catalyst-free synthesis of 3-aryl-3-hydroxy-2-oxindole derivatives by using water as the solvent: experimental and DFT studies, Asian J. Org. Chem, vol.5, pp.1334-1344, 2016.

P. N. Tosso, Y. Kong, L. Scher, R. Cummins, J. Schneider et al., Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma, J. Med. Chem, vol.57, pp.10290-10303, 2014.

J. Eberle and C. W. Knopf, Non-isotopic assays of viral polymerases and related proteins, Methods Enzymol, vol.275, pp.257-276, 1996.

S. Chander, P. Wang, P. Ashok, L. M. Yang, Y. T. Zheng et al., Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives, Bioorg. Chem, vol.67, pp.75-83, 2016.

J. H. Wang, H. L. Nie, S. C. Tam, H. Huang, and Y. T. Zheng, Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity, FEBS Lett, vol.531, pp.295-298, 2002.

Y. T. Zheng, K. Ben, and S. W. Jin, Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T lymphoid cells, Acta Pharmacol. Sin, vol.20, pp.239-243, 1999.

. Glide, L. Schrödinger, and N. York, , 2013.

E. B. Lansdon, K. M. Brendza, M. Hung, R. Wang, S. Mukund et al., Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design, J. Med. Chem, vol.53, pp.4295-4299, 2010.

W. L. Jorgensen, D. S. Maxwell, and R. J. Tirado, Development and testing of the OPLS allatom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc, vol.118, pp.11225-11236, 1996.

. Lig-prep, L. Schrödinger, and N. York, , 2013.